Abbott has received emergency use authorisation from the US Food and Drug Administration “for use by authorised laboratories and patient care settings,” the company said on Friday. CLICK HERE TO READ FULL REPORT
At 09:56 am, Abbott India's stock was trading 10 per cent higher at Rs 15,480 on the BSE, as compared to 1.8 per cent decline in the S&P BSE Sensex. A combined 34,770 equity shares have changed hands on the counter on the NSE and BSE so far.
In the past one year, the stock has zoomed 112 per cent against 24 per cent decline in the benchmark index.